Human Longevity
Overview
Human Longevity Inc. (HLI) is a biotechnology company headquartered in San Francisco, California, focused on advancing precision medicine for healthy aging, also known as longevity medicine. It was founded in 2013 by Dr. J. Craig Venter, a pioneer in human genome sequencing. Since its inception, HLI has raised over $369.8 million to fund its innovative research and development endeavors, aiming to revolutionize healthcare by focusing on preventive measures and personalized medicine.
Recent Developments
- In September 2024, Human Longevity closed an oversubscribed $39.8 million Series B financing round led by TVM Capital Healthcare, with participation from Panacea Venture and Emerging Technology Partners. The company plans to use the funds to enhance its artificial intelligence health risk platform and expand globally, especially into Europe, Asia, and Saudi Arabia.
- August 2024 saw announcements of expanding their 100+ Longevity Care Program, designed to leverage precision health data for early detection and personalized health interventions. This initiative underscores HLI's commitment to lowering biological age and prolonging healthspan.
- Earlier in 2024, Human Longevity confirmed its leading role in longevity medicine with significant investments aimed at disease prevention and supporting the transition from "sick care" to true "healthcare" across various global markets, including new expansions in Southeast Asia.
- The company continues to invest heavily in its genomics and precision medicine expertise, enabling early-stage diagnosis to maximize health outcomes and efficiency in healthcare systems.
Company Information
| Attribute | Information |
|---|---|
| Founding Date | 2013 |
| Headquarters | San Francisco, California, USA |
| Founders | Dr. J. Craig Venter |
| Revenue | Not publicly disclosed |
| Profits | Not publicly disclosed |
| Key Investors | TVM Capital Healthcare, Panacea Venture, Emerging Technology Partners |
| Industry | Biotechnology, Longevity Medicine |
| Number of Employees | Not publicly disclosed |
Early History
Human Longevity Inc. was founded in 2013 by Dr. J. Craig Venter, who is renowned for his contribution to the sequencing of the human genome. The company was envisioned to bridge the gap between genome sequencing and practical healthcare solutions, focusing primarily on extending human lifespan and improving healthspan through advanced scientific research and genetic analysis. By 2017, HLI gained unicorn status, reflecting its rapid growth and innovative approach.
Company Profile and Achievements
Human Longevity Inc. operates on a business model centered around cutting-edge genomic research and its application in proactive healthcare. Utilizing a comprehensive dataset of genetic information, it provides predictive, personalized healthcare services aimed at preempting diseases before symptoms appear.
- HLI has developed the 100+ Longevity Care program, which includes whole-genome sequencing, metabolomics, imaging technologies, and personalized health interventions.
- The company’s work in precision medicine has led to significant breakthroughs in understanding the molecular changes associated with aging, offering pathways to mitigate age-related diseases.
- HLI has also built an extensive genomics database from its ongoing studies, ranking as one of the largest privately-held genomic datasets in the world.
- Their innovative technologies and platforms have enabled the early detection of cancers, cardiovascular diseases, and neurodegenerative disorders, boosting the effectiveness of preventive care.
Current Operations and Market Position
Today, Human Longevity stands as a front-runner in longevity medicine, employing high-tech solutions to redefine healthcare from reactive treatments to preventive, individualized care. The company serves clients globally, operating key facilities in San Francisco and San Diego, while also planning expansions into Europe, Asia, and the Middle East. HLI’s competitive advantage lies in its robust genomics expertise, AI-driven health platforms, and tailored longevity programs, solidifying its market position as a leader in the burgeoning field of longevity science.
Conclusion
Human Longevity Inc.’s vision to revolutionize the healthcare landscape has positioned it as a pivotal player in longevity and precision medicine. By focusing on genomic data and preventive care, the company aims not only to extend life expectancy but to enhance the quality of life. As HLI continues its global expansion and technological advancements, its potential to impact the healthcare industry and support healthier aging societies becomes ever more significant.